

[View this email in your browser](#)**HeiQ News** | 2020#06

HeiQ Viroblock tested successfully against virus that causes COVID-19

[HeiQ Viroblock NPJ03](#) is among the first textile technologies in the world to be proven effective against SARS-CoV-2 in the laboratory. Tests conducted by Swiss textile innovator [HeiQ](#) with the [Peter Doherty Institute](#) for Infection and Immunity in Melbourne, Australia (Doherty Institute) showed that treated fabric achieved 99.99% reduction of the virus.

HeiQ Viroblock NPJ03 is a **textile treatment for industrial use**, designed to provide textiles with **antiviral** and **antibacterial properties**. The combination of silver antimicrobial technology and vesicle technology rapidly destroys enveloped viruses including coronaviruses. HeiQ Viroblock NPJ03 treated fabrics have been tested according to ISO18184 with different enveloped viruses. It has previously been tested against coronavirus 229E, another strain of virus in the Coronavirus family in face mask testing.

The latest testing with **SARS-CoV-2 virus** was conducted by researchers at the Doherty Institute, a joint venture between the University of Melbourne and The Royal Melbourne Hospital, an internationally renowned institution combining research, teaching, public health and reference laboratory services, diagnostic services and clinical care into infectious diseases and immunity.

The research project involved a disinfection test protocol that simulated the real-life interaction of small aerosol droplets contaminating clothing. A known concentration of SARS-CoV-2 virus was contacted with the sample fabric for 30 minutes followed by measurement of remaining infectious SARS-CoV-2 viruses.

The fabric sample treated with HeiQ Viroblock NPJ03 had **no infective viruses left after 30 minutes**. The result indicated a **SARS-CoV-2 virus reduction of 99.99%** relative to the inoculum control.

Carlo Centonze, Swiss co-founder and Chief Executive Officer of HeiQ Group, stated, *“The confirmation of antiviral activity of HeiQ Viroblock against SARS-CoV-2 is an important milestone. This data forms part of our ongoing efforts to help provide textiles with greater levels of protection against viruses and contribute to efforts towards mitigation of the global pandemic.”*

“HeiQ appreciates the work of the Doherty Institute in conducting these tests and the tremendous efforts of their researchers in contributing to the global understanding of the COVID-19 pandemic,” says Australian Dr. Murray Height, co-founder and Chief Science Officer of HeiQ Group.

Dr. Julie McAuley, Senior Research Officer at the Doherty Institute, stated, *“A key part of the Institute’s current COVID-19 research focus is on testing different ways to achieve an antiviral effect against the SARS-CoV-2 virus.”*

“Testing the action of different disinfectants and surface treatments is one way that our research can help provide insights towards helping to stop the pandemic”, Dr. McAuley added.

Your HeiQ Team



WEBINAR about HeiQ Viroblock

Would you like to learn more about the HeiQ Viroblock technology, the latest test results on the COVID-19 causing virus and much more? Then join our HeiQ Viroblock webinar which we offer at two different times:

- **June 22, 2020: 4-5pm CET / 10-11am EST**
- **June 23, 2020: 9-10am CET / 3-4pm CST**

June 22, 2020 – Sign up for this webinar!

June 23, 2020 – Sign up for this webinar!



Share



Tweet



Forward

Our mailing address is:
HeiQ Materials AG
Ruetistrasse 12
8952 Schlieren (Zurich)
Switzerland

Phone: +41 56 250 68 50
Fax: +41 56 250 68 41
Email: info@heiq.com

[Add us to your address book](#)
[Unsubscribe from this list](#)